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Introduction: Giant cell arteritis (GCA) is the most common large-vessel vasculitis in 
individuals older than 50 years from Western countries. The goal of the treatment is to 
achieve improvement of symptoms and clinical remission as well as decrease the risk of 
severe vascular complications.   
Areas covered: The review summarizes the main epidemiological and clinical features 
of GCA and discusses in depth both the classic and the new therapies used in the 
management of GCA.    
Expert commentary: Prednisone/prednisolone of 40-60 mg/day is the mainstay in 
GCA therapy. It yields improvement of clinical features and reduces the risk of 
permanent visual loss in patients with GCA. Other drugs are used in patients who 
experience relapses (flares of the disease) or side effects related to glucocorticoids. 
Methotrexate is the most common conventional immunosuppressive drug used as a 
glucocorticoid sparing agent. Among the new biologic agents, the most frequently used 
is the recombinant humanized anti-IL-6 receptor antibody, which is effective to improve 
clinical symptoms, decrease the cumulative prednisone dose and reduce the frequency 
of relapses in these patients. Anti-tumor necrosis factor-α therapy is not useful in GCA. 
Experience with other biologic agents, such as abatacept or ustekinumab, looks 
promising but it is still scarce.   
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Giant cell arteritis (GCA), formerly called temporal arteritis, is a large-vessel vasculitis 
that occurs in people 50 years and older [1,2**]. It is the most common vasculitis in 
elderly people from Europe and North America [1,2**]. It is possible that the gradual 
aging of the population in Western countries may have accounted for the increased 
incidence of GCA in these countries. In this regard, the peak of incidence of GCA is 
observed within the 70-80 age group [3]. The typical GCA pattern is characterized by 
the presence of cranial ischemic manifestations, such as headache, jaw claudication or 
visual loss [4,5**]. However, the advent of new imaging techniques has allowed the 
clinicians to be aware of the presence of large vessel vasculitis (LLV) involvement in 
the setting of GCA [6*], which may be asymptomatic or typically present as limb 
claudication, in some cases without the presence of the typical cranial ischemic features 
[7]. Moreover, GCA is often associated with polymyalgia rheumatica (PMR), a disease 
that affects the shoulders and proximal aspects of the arms in individuals older than 50 
years [8**]. Also, patients with LVV in the setting of GCA may present a systemic 
inflammatory response syndrome of unknown origin [9,10,11]. This clinical 
presentation is by far more frequent than limb claudication that is a typical feature of 
Takayasu arteritis, a vasculitis that is more common in young women of oriental 
background. Also, GCA patients may present as fever of unknown origin or as 
unexplained anemia [12,13]. 
Environmental factors in patients genetically predisposed may be the triggers for the 
development of GCA [1,14*]. As occurred in patients with isolated PMR, GCA is also 
more common in people of Scandinavian descent [1,2**,14*]. In contrast, GCA is rare 











with HLA class I and II molecules, particularly with HLA-DRB1*04 alleles, has been 
described [15,16].   
Regarding the pathophysiology of GCA, it has recently been demonstrated that certain 
proinflammatory cytokines play a key role in the pathogenesis of the disease [17*], 
what has led to use therapies specifically aimed to block inflammatory pathways. 
The last goal of the treatment of patients with GCA is to control the disease, not only to 
improve the symptoms. It is also very important to avoid relapses of the disease and 
reduce the long-term therapy-related side effects. Currently, the cornerstone in the 
treatment of GCA is based on the use of glucocorticoids at the initial dose of 40-60 
mg/day of prednisone until the complete remission of the symptoms is reached, 
followed by a gradual prednisone tapering. However, relapses are frequent when 
glucocorticoids are reduced and, on the other hand, prolonged glucocorticoid use 
increases the risk of potentially severe side effects in aging individuals. For this reason, 
in glucocorticoid refractory patients or in those subjects who are more predisposed to 
glucocorticoid complications, it is important to keep in mind the use of alternative 
therapies that may have a glucocorticoid-sparing effect. 
In the present review we discuss the classic management and the new biologic therapies 
used for the management of GCA.     
 
2.  Areas covered 
Since some of the readers of this review may not be familiar with this pathology, a brief 
summary of the main epidemiological and clinical data of GCA is described. It is also 
the case for the tests and procedures to make a diagnosis of GCA. With regard to 
therapy, glucocorticoids represent the mainstay of the treatment of GCA as above 











therapies, such as methotrexate can be added. Nevertheless, their effect is often modest. 
Due to this, several biologic agents, generally monoclonal antibodies directed against 
cytokines implicated in the proinflammatory cascade, have recently been used for the 
management of GCA with variable results, which will be discussed in depth in this 
review.  
2.1. What are the main clinical features of GCA? 
The classic form of GCA manifests by cranial ischemic features that are the result of the 
arteritic involvement of the cranial arteries derived from the carotid artery [1]. More 
specifically, the inflammation of branches of the external carotid artery is responsible 
for the most common manifestations of GCA, such as headache, scalp tenderness, facial 
pain or jaw claudication [8**]. However, visual loss is generally due to anterior 
ischemic optic neuropathy that is the result of the inflammation of the posterior ciliary 
arteries, branches of the ophthalmic artery, which in turn, is a branch derived from the 
internal carotid artery [18].  
In patients with cranial GCA, headache is observed in at least 80% of the cases [4]. 
Patients often complain of other cranial manifestations, such as facial pain and scalp 
tenderness. Around 40% of these patients describe jaw claudication, which is defined as 
jaw pain associated with chewing [4]. The physical examination in patients with typical 
GCA often discloses thickened and painful temporal arteries [4]. Data from recent 
reviews and population-based studies indicate that there is a progressive reduction in the 
frequency of visual ischemic events in GCA patients [18,19*,20**]. Nevertheless, these 
ominous complications are observed in many patients with GCA, being permanent 
visual loss observed in at least 12.5% of the biopsy-proven GCA patients 
[18,19*,20**]. Transient visual loss can precede the development of irreversible visual 











visual loss [18]. In others, however, blindness is not preceded by any previous ischemic 
visual manifestations. Cerebrovascular accidents may be observed at the time of disease 
diagnosis or within the first month after GCA diagnosis in around 3% of patients in 
whom this vasculitis is confirmed by a temporal artery biopsy [20**,21]. Strokes seen 
shortly after the diagnosis of GCA occur more commonly in vertebrobasilar territory 
than in the territory of the carotid artery [21]. In contrast, as observed in elderly people, 
strokes seen in the prospective follow-up of these patients are more common in the 
carotid territory [22]. Aortic aneurysmal disease may be a late complication seen over 
the extended follow-up of patients with GCA [23,24]. Some investigators have 
emphasized the relevant role of the traditional cardiovascular risk factors (CVRF) in the 
development of aortic aneurysms in these patients [23]. In this regard, the presence of 
traditional CVRFs prior to the onset of GCA, especially hypertension, was found to be a 
risk factor for the development of further severe ischemic complications in these 
patients [25]. The main clinical features of patients with the typical pattern of cranial 
GCA are summarized in Table 1 [26]. 
Patients with GCA and LVV involvement may have stenosis of the primary and 
secondary branches of the aorta. In some cases, they do not complain of the typical 
cranial ischemic manifestations. Therefore, clinician should be aware of the potential 
risk of clinical signs of occlusive manifestations in GCA, mainly claudication of the 
extremities, due to subclavian, axillary or brachial artery stenosis, which yield clinical 
signs of occlusive manifestations, such as claudication of the extremities and tissue 
gangrene [24].     
2.2. GCA and PMR, implications in the management 











Besides the typical bilateral shoulder girdle involvement, patients with PMR also have 
severe bilateral pain and stiffness involving the arms and less commonly the neck, the 
pelvic girdle and the proximal aspects of the thighs [1,2**,8**]. PMR patients complain 
of morning stiffness generally lasting more than 45-60 minutes. They experience 
problems to carry out daily life activities, such as combing or dressing, which are more 
severe in the morning [2**,8**]. Although PMR may be an isolated condition, up to 
40%-50% of patients with classic cranial features of GCA have PMR manifestations 
[2**,27].  
Some authors consider that patients presenting as an isolated PMR, without any clinical 
evidence of GCA, in whom imaging signs of LVV involvement is found, are not 
predisposed to suffer vascular ischemic complications of GCA [28]. However, PMR 
manifestations may be the presenting feature in 20% of patients who later experience 
the typical cranial ischemic manifestations of GCA [29]. A population-based study 
showed that patients with both isolated PMR and GCA associated to PMR 
manifestations have in most cases elevation of the erythrocyte sedimentation rate 
(ESR). However, isolated PMR patients have less commonly anemia and 
thrombocytosis than those with PMR associated with the classic biopsy-proven GCA 
[30]. Also, the mean ESR is lower in patients with isolated PMR than in those with 
GCA associated to PMR [30].  
Since the initial dose of prednisone used in isolated PMR to improve symptoms is lower 
than that required to prevent the risk of blindness in GCA [2**], clinicians should be 
aware of the risk of blindness in some GCA patients presenting as isolated PMR. In this 
regard, relapses of the disease characterized by the presence of typical features of GCA, 
such as cranial ischemic manifestations, upper extremity vascular insufficiency due to 











reported in the follow-up of adequately treated patients initially diagnosed as having 
isolated (“pure”) PMR [31**]. These observations highlight the need of close follow-up 
to patients with isolated PMR due to the frequent overlap between these two diseases 
[31**].  
A point of interest is to determine how clinicians can decipher the therapeutic response 
for the GCA and PMR components in patients who have both conditions. In this regard, 
PMR symptoms may improve rapidly with a dose of prednisone between 12.5 and 25 
mg/day. However, this dose is considered insufficient to prevent the development of 
visual loss associated with GCA [32]. Moreover, the dose of glucocorticoids required to 
treat GCA patients who present with visual ischemic manifestations is much higher (at 
least 60 mg/day of prednisone) than that required to yield rapid improvement of PMR 
symptoms. 
2.3. How can we make a diagnosis of GCA? 
The classic approach to make a diagnosis of GCA is based on a positive temporal artery 
biopsy. In general, in subjects with the typical pattern of cranial GCA, a biopsy of the 
temporal artery on the most symptomatic side of at least 1 cm length is sufficient to 
make a histological diagnosis of GCA [33]. Biopsy-proven GCA patients exhibit 
histological features in the temporal artery that include disruption of the internal elastic 
lamina with an inflammatory infiltrate composed mainly of mononuclear cells and giant 
multinucleated cells in approximately 50% of the cases [34]. A positive temporal artery 
biopsy for GCA was included among the criteria proposed by the American College of 
Rheumatology (ACR) to classify a patient as having GCA [35]. Besides an abnormal 
temporal artery biopsy, another four criteria (age at disease 50 years or older, new onset 
of headache, temporal artery abnormality on physical examination of the temporal 











classification criteria [35]. For the purpose of classification, a patient was considered to 
have GCA if he/she fulfilled 3 of these 5 criteria [35]. Although the ACR classification 
criteria are useful to identify patients with the classic cranial pattern of GCA, they are 
often inadequate to identify GCA patients presenting with LVV [36*]. A study that 
assessed differences between 120 GCA patients with LVV involvement and 212 GCA 
patients with the typical cranial ischemic manifestations of the disease showed that 
those with LVV involvement were younger and had longer duration of symptoms at the 
time of disease diagnosis than those with the classic pattern of cranial GCA [36*].   
Several studies have confirmed that Doppler ultrasonography (US) of the temporal 
artery may be an alternative to the classic approach of performing a temporal artery 
biopsy to make a diagnosis of GCA, in particular in those patients presenting with the 
typical cranial pattern of the disease. In these cases, the assessment of the temporal 
arteries by Doppler US can disclose the typical finding consisting of edema, 
characterized by a dark, hypoechoic, circumferential wall thickening “halo” around the 
lumen of the temporal artery that does not disappear upon compression [37]. The 
compression sign should always be performed in the presence of a suspected halo 
because it has demonstrated to be a robust marker with excellent inter-observer 
agreement [37]. Other findings that can be disclosed by US in patients with arteritic 
involvement of the temporal artery are the presence of stenosis and occlusion [37]. In 
contrast, the absence of this “halo sign” involving the temporal artery makes the 
diagnosis of cranial GCA unlikely [38]. 
The use of imaging techniques, such as the positron emission tomography (PET), may 
allow to disclose the presence of LVV involvement in patients presenting as isolated 
PMR without cranial ischemic manifestations [8**]. Apart from the PET/computed 











resonance imaging (MRI) angiography, have contributed to identify the presence of 
LVV involvement in patients with GCA and PMR [6,39,40**,41,42].  These new 
imaging techniques have been of great help to redefine the actual spectrum of GCA, 
emphasizing the relevance of the extracranial LVV involvement in these patients 
[40**]. However, CT-angiography is not any more recommended. PET is costly and 
some experts do not recommend PET as the preferred diagnostic tool. Moreover, in 
contrast to MR-angiography, PET does not provide sufficient information regarding the 
vessel wall, and its relevance in the follow-up of patients with LVV requires further 
investigation. Modern MRA techniques, such as the dark-blood technique of 
extracranial arteries, constitute promising tools for the diagnosis of GCA. Interestingly, 
the recent European League Against Rheumatism (EULAR) recommendations for the 
use of imaging in patients with LVV include the use of an early imaging technique in 
individuals in whom LVV is suspected [43**].  
According to this group of experts, US should be the first choice for the diagnosis of 
GCA. They consider that CT-scan or PET may be used indistinctly [43**]. In a study by 
Bley et al comparing color-coded duplex US and high-resolution MRI in the diagnosis 
of GCA, the sensitivity of high-resolution MRI and US compared with the temporal 
artery biopsy was 83% and 79%, respectively whereas the specificity was 71% and 59% 
[44]. 
2.4. Importance of early treatment in patients with GCA 
The final goal of GCA therapy is to induce the remission of the disease, not only to 
improve the symptoms. It is also important to avoid relapses and the development of 
irreversible complications as well as the occurrence of severe treatment-related side-











A higher physician awareness is probably the reason for the progressive reduction in the 
frequency of visual ischemic complications and permanent visual loss observed over the 
last two decades in different population-based studies [3,19*,45*]. Nevertheless, GCA 
remains as one the main causes of blindness in elderly people in Western countries 
[19,45*]. 
Another important point regarding GCA therapy is the urgency of treatment even before 
the diagnosis is confirmed, especially when ocular symptomatology appears (diplopia, 
amaurosis fugax, transient visual loss) because of the risk of acute and permanent visual 
loss. This is an important challenge in real life which requires urgent decision and 
therapy. In these cases, it is advisable to start treatment before the diagnosis can be 
confirmed and other causes have been excluded. 
Once the diagnosis has been made, patients must be prospectively followed-up to 
reduce the risk of cardiovascular complications. Population-based studies from 
Southern Europe reported in the past decade highlighted the influence of the traditional 
CVRFs in the risk of severe ischemic complications [21,25,46]. Also, socio-economic 
deprivation was associated with ischemic manifestations in patients with GCA from the 
UK [47].    
A meta-analysis disclosed that the use of antiplatelet or anticoagulant therapies before 
GCA diagnosis is not associated with a decrease in the incidence of severe ischemic 
complications when the disease is diagnosed [48]. However, the use of antiplatelet or 
anticoagulant therapies once the diagnosis of GCA has been made seems to reduce the 
risk of further ischemic events [48]. In this regard, a committee of experts supported by 
EULAR recommended the use of low-dose aspirin in all patients with GCA [49]. 
Finally, the evolution of the GCA must be seen globally, from a point of view of both 











two fields, which would make it necessary to rule out an intercurrent disease different 
from GCA. In case of doubt, clinicians should use imaging examinations, such as MRI 
or PET, which if positive, will confirm that the process continues still active. 
2.5. Treatment of GCA: Classic and new therapies  
Table 2 summarizes the main therapies used in patients with GCA [26].  
2.5.1. Glucocorticoids. The pivotal drugs 
Glucocorticoids are the mainstay of therapy in patients with GCA [50*]. Whereas the 
initial dose of prednisone/prednisolone recommended in patients with isolated PMR to 
achieve a rapid improvement of symptoms ranges between 12.5 and 25 mg/day 
[8**,51], high-dose glucocorticoid therapy is required to yield remission in patients 
with GCA [49]. With respect to this, the initial prednisone/prednisolone dose in 
individuals with GCA ranges between 40-60 mg/day for 3-4 weeks [34,50]. In most 
cases, improvement of cranial symptoms, such as headache or scalp tenderness, is seen 
within the first 24 to 72 hours after the onset of glucocorticoid therapy. It is also 
applicable for PMR manifestations. Some authors recommend starting with a 
prednisone dose of 40 mg/day in GCA patients without severe ischemic complications 
[14*,15,25]. However, the experts from the EULAR suggest using an initial dose of 
prednisolone of 1 mg/kg/day (maximum 60 mg/day) [49]. In keeping with this 
approach, there is general agreement on the use of an initial dose of 60 mg/prednisone 
or prednisolone/day or the initial administration of intravenous methylprednisolone 
pulse therapy (1g daily for 3 consecutive days) in patients who present with severe 
ischemic manifestations, in particular if they have visual impairment [18,34]. GCA 
patients with visual loss lasting more than 24 hours have a poor response to 
glucocorticoids [52,53]. Therefore, intensive glucocorticoid therapy must be started 











Regarding the use of intravenous glucocorticoid therapy in patients without visual 
ischemic manifestations, a study showed that an initial treatment of GCA with 
intravenous glucocorticoid pulses (methylprednisolone 15 mg/kg of ideal body 
weight/day) for 3 consecutive days along with oral prednisone (40 mg/day) yielded 
faster tapering of oral prednisone and higher rate of patients who achieved sustained 
remission of the disease after discontinuation of treatment [54]. Moreover, patients who 
started with intravenous methylprednisolone along with oral prednisone had a lower 
median dose of prednisone a fewer relapses than those from the control group who only 
received oral prednisone [54]. Although these results look promising, they were based 
on a series of only 27 patients [54]. In this regard, another study did not support a long-
term glucocorticoid -sparing effect of intravenous methylprednisolone in the 
management of non-complicated patients with GCA [55]. 
In most cases, the acute phase proteins ESR and C-reactive protein (CRP) become 
normal within 2 to 4 weeks after the onset of the glucocorticoids [50,56]. Afterwards, 
the glucocorticoid dose should be gradually tapered [49]. Based on our experience with 
a large series of 287 biopsy-proven GCA patients [21], we usually taper 5 mg of 
prednisone every 2-4 weeks up to 25 mg/day, generally every 2 weeks. Then, we carry 
out prednisone reduction more slowly by 2.5 mg every 2-4 weeks until the dose reached 
is 10 mg/day and later by approximately 2.5 mg every 2 months [57]. However, we 
realize that our proposed recommendation to lower prednisone does not correspond with 
the EULAR recommendations [49]. In this regard, EULAR experts recommended 
decrease the dose of prednisone more rapidly, reaching a dose 10-15 mg/day of 
prednisone at week 12 if patients had not experienced relapses of the disease [49]. In 
this regard, classic studies have emphasized that prolonged use of glucocorticoids in 











gastrointestinal bleeding, hypertension, cataracts and infections that in some cases may 
be fatal [58,59]. 
Close monitorization of GCA patients during the follow-up, searching for relapses of 
the disease and assessing routine laboratory markers of inflammations is mandatory.  
In general, clinicians gradually taper the glucocorticoids in the follow-up if patients 
have no symptoms of GCA and the acute phase proteins ESR and CRP are normal 
[57,60]. Also, at the time of tapering prednisone, it is important to keep in mind that 
alternate day glucocorticoid use should not be performed because it often leads to a 
relapse of the disease [34,49]. 
Typical relapses of GCA occur with an important rise of ESR (≥ 40 mm/1st hour) and 
they are associated with disease-related manifestations such as headache or other cranial 
manifestations, PMR, fever or constitutional symptoms. However, sometimes relapses 
of the disease are associated with only mild elevation of ESR. Therefore, relapses are 
considered to be present when clear and worsening symptoms occurred with an ESR 
equal to or greater than 20 mm/1st hour [61]. A population-based study disclosed that 71 
(41%) of 174 biopsy-proven GCA patients experienced relapses of the disease. The total 
duration of corticosteroid therapy was significantly longer in those patients who had 
relapses [61]. In keeping with these results, 57 (45.6%) of 125 patients from Olmsted 
County (Minnesota, USA) diagnosed with GCA between 1950 and 1991 had relapses 
[59]. Furthermore, 103 (86%) of them experienced adverse events associated with 
glucocorticoid use. A higher cumulative dose of glucocorticoids was associated with the 
development of adverse glucocorticoid side effects [59]. The high frequency of relapses 












Another situation that may require the use of glucocorticoid-sparing agents is in 
glucocorticoid resistant PMR patients, in whom a LVV is disclosed by imaging 
techniques such as PET/CT scan when they are evaluated to rule out a relapse [62].   
2.5.2. Conventional immunosuppressive drugs: Role as glucocorticoid sparing agents 
Conventional immunosuppressive agents are used in patients with GCA to reduce the 
duration of the glucocorticoid therapy, in particular in patients who experience relapses 
of the disease [49]. These agents are also used in individuals with severe glucocorticoid-
related side effects.  
Methotrexate (MTX) is the most commonly conventional immunosuppressive drug used 
as a glucocorticoid sparing agent [49]. Three randomized controlled trials of MTX as 
adjunctive therapy to glucocorticoids have been reported [63,64*,65].  
The first trial included 21 patients with GCA who were treated with high dose 
glucocorticoids along with MTX (n=12) or placebo (n=9) [63]. However, no significant 
difference in the cumulative glucocorticoid dose, number of weeks to reach 
discontinuation of glucocorticoids, weeks required to taper prednisone to less than 10 
mg/day and bone mineral density in lumbar spine or hip at one year were observed 
between those treated with MTX or placebo [63]. In contrast, in another study that 
included 50 biopsy-proven GCA patients from a single center with less than 2 weeks of 
treatment with more than 10 mg/day of prednisone, significant differences between 
MTX -treated and the placebo group were seen [64]. In this second study, a single dose 
of 10 mg/week of oral MTX or placebo was started and maintained throughout the 
period of study. Discontinuation of MTX and placebo was allowed after 24 months of 
follow-up if the patient was in clinical remission. In this study, the initial dose of 
prednisone was 60 mg/day, which was gradually tapered [64]. In this trial, MTX use 











The third randomized clinical trial on MTX in GCA enrolled 98 patients from different 
centers [65]. In the study the initial dose of prednisone was 1 mg/kg/day (maximum 60 
mg/day) along with 0.15 mg/kg/week MTX (increased to 0.25 mg/kg/week, for a 
maximum weekly dose of 15 mg) or placebo. The median dose of MTX was 15 
mg/week. This study did not show any beneficial effect of the use of MTX along with 
glucocorticoids in GCA patients [65]. The frequency of treatment failure after 12 
months was similar in both groups [65]. No differences between MTX and placebo 
groups in the cumulative glucocorticoid dose were observed [65].   
A meta-analysis of these three-randomized placebo-controlled trials yielded a modest 
role of MTX (10-15 mg/week) to reduce the frequency of relapses and decrease the 
cumulative prednisone dose [66].  
With regard to the use of other conventional immunosuppressive agents, azathioprine 
use led to lower requirement of glucocorticoids in a double blind randomized placebo-
controlled study in patients with GCA or PMR [67]. However, this study only included 
31 patients.   
Although a study that included 12 patients with PMR and 11 with GCA suggested a 
potential efficacy of leflunomide as a glucocorticoid-sparing agent [68], experience with 
this drug in GCA is scarce. Cyclosporine A, hydroxychloroquine or dapsone did not 
show beneficial effects as glucocorticoid-sparing agents in patients with GCA [69]. In 
this regard, a meta-analysis that assessed the efficacy of different conventional 
immunosuppressive drugs showed that prednisone or prednisolone alone is in most 
cases similar in terms of efficacy and safety to the use of glucocorticoids with 
adjunctive immunosuppression in patients with GCA [69].  
2.5.3. A new era for GCA therapy: Role of the biologic agents 











Over the last two decades, biologic therapies, in particular anti-TNF-α agents, have been 
used in patients with rheumatic diseases refractory to conventional drugs. They were 
also tested in patients with GCA. The most important trial was performed by Hoffman 
et al. They carried out a phase II study, randomized, double-blind, placebo-controlled 
trial to assess whether the chimeric monoclonal antibody-infliximab was a useful in 
GCA patients with new onset disease [70]. Patients included into the study (n= 44) were 
required to have experienced resolution of symptoms and normalization of ESR 
following treatment with 40-60 mg/day of prednisone/prednisolone and to have been in 
remission of the disease for at least 1 week before randomization [70]. All of them 
received an initial dose of 40-60 mg/prednisone/day. Patients were randomized to 
receive placebo (n=16) or infliximab 5 mg/kg/infusion (n=28) at baseline (week 0) and 
at weeks 2, 6, 14, 22, 30, 38 and 46. However, after 22 weeks of follow-up, there were 
no differences between infliximab and placebo-treated patients in terms of patients free 
of relapses or in the cumulative doses of prednisone [70]. The second more important 
study on anti-TNF agents was done with the human anti-TNF monoclonal antibody 
adalimumab [71]. This biologic agent was administered for 10 weeks to patients with a 
recent diagnosis of GCA. Adalimumab did not show superiority in the number of 
patients in remission on less than 0.1 mg/kg of prednisone at 6 months. Furthermore, the 
use of this biologic agent was associated with an increased risk of infection [71]. 
Likewise, etanercept also failed to demonstrate efficacy in GCA [72]. Therefore, anti-
TNF therapy is not generally indicated in patients with GCA. 
2.5.3.2 Interleukin (IL)-6 inhibitors  
IL-6 is a pivotal proinflammatory cytokine that is produced in the inflamed arteries of 
patients with GCA [73]. It is also expressed in the monocytes of these patients [74]. IL-











increased IL-6 levels in the peripheral circulation [75,76]. Persistence of high serum IL-
6 levels suggests the presence of disease activity in glucocorticoid-treated patients with 
GCA [76]. Following the use of glucocorticoids there is a rapid decrease of IL-6 levels 
that generally correlates with a reduction in the activity of the disease [77,78]. Because 
of that, IL-6 blockade was considered as a potential therapeutic option in patients with 
GCA [79]. Interestingly, Seitz et al reported for first time a series of GCA patients 
successfully treated with the anti-IL-6 receptor (tocilizumab) [80]. Additional single 
cases and small case series indicated that the use of the anti-IL-6 receptor tocilizumab 
could be effective in both newly diagnosed and relapsing patients with GCA [81,82]. 
Also, retrospective studies supported these promising observations [82*,83]. In this 
regard, an open-label, retrospective, multicenter study on 22 patients classified as 
having GCA according to the 1990 ACR Classification Criteria, showed that the anti-
IL6-receptor tocilizumab was useful in patients with refractory and relapsing GCA 
[82*]. In this series all the patients had been treated with high dose prednisone and 19 of 
them had also received conventional immunosuppressive drugs and/or biologic agents. 
The reason for using tocilizumab (8 mg/kg every month) in these patients was absence 
of efficacy and in some cases severe adverse events related to glucocorticoids or 
immunosuppressive agents [82*]. Tocilizumab yielded a rapid and maintained clinical 
response in most of them (19 of 22) along with significant reduction of acute phase 
proteins CRP and ESR [82*]. Also, the use of this biologic agent allowed to perform a 
successful prednisone tapering in 20 out of the 22 patients [82*]. In keeping with these 
findings, another retrospective multicenter study showed beneficial effect of 
tocilizumab in 28 of 34 GCA patients [83]. Nevertheless, in this study, six patients 
experienced side effects that could possibly be related to the treatment with tocilizumab 











Confirmatory data on the efficacy of the anti-IL6 receptor tocilizumab in the 
management of GCA has recently been reported in two placebo-controlled trials 
[84**,85**]. The first of them, a phase 2 study, was not truly a double-blind study 
because of the assessor judging clinical response was not blinded to the laboratory 
findings, being able to make changes in the treatment during the follow-up in function 
of the appearance of laboratory alterations [84**]. This study included 30 patients with 
GCA (23 of new diagnosis and 7 with relapsing disease) [84**]. Patients were 
randomized to receive intravenous anti-IL-6 receptor tocilizumab at a dose of 8 mg/kg 
every 4 weeks plus prednisolone (n=20 patients) or placebo infusion every 4 weeks plus 
prednisolone in the remaining patients (n=10). The primary endpoint was the percentage 
of patients who reached complete remission at a prednisolone dose of 0.1 mg/kg/day at 
week 12. Interestingly, 85% of the 20 tocilizumab-treated GCA patients experienced 
complete remission versus only 40% of the patients from the placebo group at week 12 
(p=0.03) [84**]. Glucocorticoids were rapidly tapered and discontinued by 36 weeks 
after the onset of tocilizumab. Due to this, the cumulative prednisolone dose was 
reduced in the tocilizumab-treat d group. In this regard, after 52 weeks the cumulative 
prednisolone dose was 43 mg/kg in the group treated with tocilizumab and 110 mg/kg 
in the placebo group (p=0.0005). Moreover, relapse-free survival at 52 weeks was 
significantly higher in the tocilizumab-treated group than in placebo group (85% versus 
20%; risk difference 65%; p=0.001). Also, patients from the placebo group suffered 
more serious side effects than those treated with tocilizumab (50% versus 35%) [84**]. 
While patients were receiving tocilizumab, only one patient experienced a relapse and 
no relapses occurred after discontinuation of prednisolone in the subgroup of patients 
undergoing tocilizumab therapy. Nevertheless, after one-year tocilizumab was 











50% of the patients previously treated with tocilizumab. However, the relapses were not 
associated with irreversible damage [84**]. This study showed that tocilizumab was 
effective to induce remission, prevent relapses, and decrease the cumulative 
prednisolone dose. By contrast, an important limitation of this study was that CRP and 
clinical response were considered together as a combined final endpoint, which can 
overestimate the actual number of remissions, due to the favorable effect of tocilizumab 
in decreasing CRP [84**]. 
Much stronger data supporting the benefit and safety of the anit-IL-6 receptor therapy 
were reported in the tocilizumab in GCA (GiACTA) trial [85**]. The central hypothesis 
of this phase 3 trial was to confirm a powerful glucocorticoid-sparing effect mediated 
by tocilizumab. For this purpose, the investigators enrolled 251 patients over 22 months 
from 14 countries and 76 sites (61 from Europe and from 15 North America). Among 
them, 119 were newly diagnosed and 132 relapsing patients diagnosed with GCA by 
using the ACR Criteria or by imaging techniques showing LVV. Patients were split into 
four branches: a weekly dose of tocilizumab (162 mg) given subcutaneously plus a 26- 
week prednisone taper, another group in which patients received tocilizumab (162 mg) 
given subcutaneously every other week along with a 26-week prednisone taper, a third 
group in which patients received weekly placebo along with a 26-week prednisone 
taper, and a fourth group of weekly placebo plus a 52-week prednisone taper. 
Tocilizumab-treated patients reached sustained remission more commonly than those 
placebo-treated at 52-week. Fifty-six percent of the patients receiving subcutaneous 
tocilizumab every week and 53% of those treated with subcutaneous tocilizumab every 
other week achieved remission. In contrast, the placebo plus 26-week prednisone taper 
and the placebo plus 52-week prednisone taper only obtained sustained remission in 











statistically significant with p-values <0.001. Relapses of the disease were less common 
in tocilizumab treated patients (23% in those receiving tocilizumab every week and 26% 
in those treated with tocilizumab every other week) than in those included in the 26 and 
52-week placebo arms (68% and 49%, respectively). Tocilizumab therapy also led to a 
statistically significant glucocorticoid-sparing effect. Patients treated with tocilizumab 
were longer time free of relapses. This was more evident in the subgroup of GCA who 
had suffered relapses before randomization. Also, tocilizumab-treated patients had 
lower serious adverse events than those treated with placebo [85**]. Based on those 
results the weekly use of subcutaneous tocilizumab has been approved by the United 
States FDA and the European Commission for the treatment of GCA.  
Nevertheless, the GiACTA trial has important limitations in the evaluation of its results. 
Almost half of the patients (47%) had a disease of short time of evolution (diagnosis ≤ 6 
weeks before inclusion). Furthermore, remission was defined as the absence of relapse 
(flare) plus normalization of the CRP, and relapses were defined as the recurrence of 
signs or symptoms or an elevation of the ESR. Given that tocilizumab is a suppressor of 
both CRP and ESR, it is unclear if this agent leads to true improvement of vasculitis 
without histopathology or imaging exams confirmatory of amelioration [85**]. 
Intriguingly, none of the randomized tocilizumab trials mentioned presented data on the 
most severe complication of GCA (“vision loss”), which is also an important limitation 
of these studies. Biologics can also cause serious adverse effects, especially in the 
elderly or immunosuppressed patients. 
Interestingly, open-label studies suggest that tocilizumab may also be effective in cases 
of isolated aortitis and in Takayasu´s arteritis [86,87]. Therefore, tocilizumab appears to 











together these observations, we support its use in LVV patients with relapsing disease 
[88].  
The potential efficacy of a human anti-IL6 monoclonal antibody, different from the 
previously discussed anti IL6-receptor tocilizumab, is currently under investigation in a 
phase 3 trial (ClinicalTrials.gov Identifier NCT02531633). Also, sarilumab, another 
anti-IL-6 receptor agent, is going to be tested for efficacy and safety in GCA.  
2.5.3.3 Other biologic agents. Abatacept and Ustekinumab 
Abatacept, a fusion protein composed of the Fc region of the immunoglobulin IgG1 
fused to the extracellular domain of CTLA-4, blocks the co-stimulatory signal required 
for T cell activation. A recent study has evaluated the safety and efficacy of intravenous 
abatacept in patients GCA [89**]. For this purpose, patients with newly-diagnosed or 
relapsing GCA were treated with abatacept (10 mg/kg intravenously) on days 1, 15, 29, 
and week 8, together with prednisone. At week 12, 41 patients who had achieved 
remission underwent blindly randomization to receive either monthly placebo 
intravenous infusions (n=21) or monthly intravenous abatacept (n=20). Patients 
included in both study arms rec ived a standardized prednisone taper with 
discontinuation of prednisone at week 28. Relapse-free survival at 12 months was 
higher in those treated with abatacept (48% in abatacept-treated versus 31% in the 
placebo group, p=0.049). Also, the median duration of remission was longer in the 
group treated with abatacept (9.9 months in abatacept-treated versus 3.9 months in those 
undergoing intravenous placebo; p=0.023). The primary outcome of the study, relapse-
free survival at 12 months, was reached by 48% patients who received abatacept and 
31% of those with placebo (p=0.049) [89**]. Moreover, the duration of remission was 
longer in those treated with abatacept (on average 6 months). No differences in the 











additional studies should be conducted to confirm these results. For this reason, we do 
not use intravenous abatacept in relapsing GCA patients treated in our Division. On the 
other hand, to our knowledge, the abatacept multicenter trial was discontinued.   
Ustekinumab, a monoclonal antibody directed against IL-12/ 23p40 complex, may 
block the inflammatory Th1 (IL-12) and Th17 (IL-23) pathways. Patients with 
refractory GCA treated with ustekinumab obtained an effect of modulating the 
Th1/Th17/Treg imbalance [90*]. After three injections of 45 mg of ustekinumab given 
at week 0, week 4 and week 16, a marked reduction of Th1 and Th17 cells and 
cytotoxic T lymphocytes was observed compared to baseline. Also, after three 
injections of this biologic agent, a significant increase of Tregs was observed [90*]. 
Moreover, an open label study that included 14 patients with refractory GCA has shown 
promising results following ustekinumab therapy [91*]. In this study, the patients were 
classified as having GCA according to the ACR Criteria and had long disease duration 
(median 30 months). This relapsing series of patients were treated with ustekinumab 90 
mg at weeks 0, 4, and then every 12 weeks (median 8 months) [91*]. Ustekinumab use 
was associated with a reduction of the glucocorticoid dose [91*]. Glucocorticoids were 
successfully discontinued in 3 patients and in 8 patients ustekinumab allowed the 
discontinuation of the baseline immunosuppressive agents. Although there were not 
relapses while the patients were undergoing ustekinumab therapy, they were common 
once that ustekinumab was discontinued. To further support these data on ustekinumab 
therapy in GCA there is an ongoing phase 2 trial (ClinicalTrials.gov Identifier 
NCT02955147). 
Recent data on an experimental model in mice have shown that a disruption of the 











pathogenic remodeling of the inflamed arterial wall, which opens a new avenue in the 
pathogenesis and therapy of GCA [92]. 
2.5.3.4 Small molecules: JAK/STAT inhibitors 
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
pathway plays an important role in the cellular regulation in humans. A great number of 
cytokines, such as IL-2, IL-4, IL-6, IL-7, IL-9, IL-12, IL-15, IL-21, IL-23, IL-27, type 1 
interferon and interferon-gamma (IFN-γ), which are immune relevant mediators 
involved in the pathogenesis of autoimmune diseases, use this pathway to transduce 
intracellular signals [93**]. Ligand binding of these immune mediators to their cell 
surface receptors leads to activation of associated JAKs. In turn, the activated JAKs 
increase their kinase activity, recruit, bind and activate STAT. The STAT molecules 
constitute hetero- or homo-dimers which translocate to the nucleus, inducing 
transcription and expression of target genes. Polymorphisms of JAK and STAT genes 
have been associated with autoimmune diseases [93**]. IFN-γ is strongly implicated in 
the pathogenesis of GCA and in the process leading to vascular luminal occlusion [94]. 
High concentrations of IFN-γ messenger RNA are observed in the temporal arteries of 
patients with GCA who present severe ischemic complications [94]. 
STAT-1 signaling regulates the activity of vascular dendritic cells, controlling T cell 
trafficking and retention of inflammatory T cells in the vascular lesions [95, 96**]. 
Interestingly, IFN-γ is the major inducer of STAT-1. In a mouse model of experimental 
GCA, dexamethasone suppressed the innate immunity with inhibition of dendritic cell 
activation, IL-6 and IL-1β expression in the vascular lesions. However, this 
glucocorticoid maintained IFN-γ-producing Th1 unaffected [95]. In contrast, the 
JAK/STAT-inhibitor tofacitinib, a kinase inhibitor for JAK3 and JAK1, prevented T 











model of vascular inflammation in human arteries engrafted into immunodeficient mice 
that were reconstituted with T cells and monocytes from patients with GCA [95, 96**]. 
Tofacitinib also yielded a marked reduction of the blood levels of IFN-γ in this 
vasculitis-induced model [95, 96**].   
Currently there is a phase 2 trial evaluating the effect of baricitinib (inhibitor of JAK1 
and JAK2 inhibitor) in patients with relapsing GCA (ClinicalTrials.gov Identifier 
NCT03026504). 
2.5.4. Prevention of osteoporosis  
Since glucocorticoids are the classic treatment in GCA, osteoporosis prophylaxis has to 
be kept in mind in the management of GCA [97,98]. Glucocorticoids induce lower 
activity and higher death rate of osteoblasts and prolonged lifespan of osteoclasts. This 
yields a reduction in bone formation and increases bone resorption [99,100]. The effect 
of glucocorticoids on the gut, kidney, parathyroid glands and gonads also leads to 
alteration in the calcium/phosphate metabolism.   
Calcium and vitamin D along with a potent oral bisphosphonate, such as alendronate 
(70 mg/wk) or risedronate sodium (35 mg/week), should be considered in the 
management of GCA patients undergoing glucocorticoid therapy [101]. Intravenous 
bisphosphonates may be used in people intolerant of oral bisphosphonates. 
Administration of intermittent parathormone (PTH) may induce formation of new bone 
and counteract the bone loss induced by the glucocorticoids [102]. In long-term 
glucocorticoid-treated patients, switching from bisphosphonates to denosumab, a potent 
antiresorptive agent, yielded gain of the spinal bone density and suppression of bone 
turnover markers after 12 months of therapy [103].  
Patients with very high body mass index and those receiving high doses of 











these patients, oral calcidiol supplementation was found to be more effective than 
cholecalciferol to reach adequate 25(OH) vitamin D levels [104]. 
2.6. Conclusions  
GCA is the most common vasculitis in elderly people from Western countries. 
Glucocorticoids are the mainstay of treatment GCA. They generally lead to 
improvement of symptoms of GCA. However, they are frequently associated with side 
effects. Alternative therapies are used in patients with refractory or relapsing disease. 
They are also used in an attempt to “spare” glucocorticoids. MTX, the most commonly 
used conventional immunosuppressive drug for the management of refractory GCA, has 
mild beneficial effect. Whereas anti-TNF-α agents yielded poor results, the use of anti-
IL-6 receptor tocilizumab has proved to be effective in the management of GCA. This 
result is of potential relevance in patients with refractory disease. Abatacept and 
ustekinumab have shown potential beneficial effect in patients with GCA. The use of 
JAK/STAT inhibitors in the management of GCA is still under investigation.  
 
3. Expert commentary   
Figure 1 summarizes our point of view on the treatment of GCA. 
Based on our own experience, we strongly support the use of prednisone (initial dose of 
40-60 mg/day) in patients with GCA. We and others have observed that glucocorticoids 
are associated with a rapid improvement of most clinical features and have proved to 
prevent the risk of blindness. However, we previously reported that glucocorticoids do 
not yield visual recovery in most cases if therapy is not started soon when the visual 
loss occurred [52]. Few GCA patients experience visual improvement when 











Therefore, we believe that early diagnosis is essential to improving patients' outcomes 
and to prevent irreversible damage, such as blindness, in patients with GCA.  
We also support the classic approach for the diagnosis of cranial GCA by performing a 
temporal artery biopsy [34]. However, experts consider that the temporal artery biopsy 
should be replaced by the temporal artery sonography [43**]. Nevertheless, we also 
support the use of the imaging techniques for the diagnosis and monitoring of patients 
with LVV. We use PET/CT scan when an extracranial GCA is suspected, in particular 
in patients with persistent PMR despite glucocorticoid therapy [62**].  
One of our major concerns in the management GCA comes from the high frequency of 
relapses when the prednisone dose is tapered [61]. The frequency in our series (41%) 
[61] was similar to that found in Reggio-Emilia (Italy) (57 [37%] of 157 biopsy-proven 
patients) [105]. In our experience, relapses occur mainly when prednisone dose is lower 
than 10-15 mg/day [61]. Relapsing patients require longer duration of glucocorticoid 
therapy. In these patients, we use MTX as the first glucocorticoid-sparing agent. 
However, as previously described, the effect of MTX is often modest [66*]. We have 
obtained good results by the use of the anti-IL-6 receptor tocilizumab in GCA patients 
refractory to glucocorticoids and MTX [82*]. Our clinical experience is in line with data 
from placebo-controlled studies that have supported the use of this biologic agent in 
GCA [84**,85**]. However, relapses are not uncommon when tocilizumab is 
discontinued. Moreover, autopsy results have shown have active vascular inflammation 
in patients who were apparently in clinical remission following tocilizumab therapy 
[106].   
Although the GiACTA study on the use of the anti-IL-6 receptor tocilizumab 
constituted a major step forward in the management of GCA [85**], we are concerned 











relapses under ongoing tocilizumab use. Therefore, we wonder if there was a true 
glucocorticoid-sparing effect. Another criticism on this trial was that in this study the 
increase of CRP levels was proposed as a marker of relapse under tocilizumab, while 
we know that CRP and other acute phase proteins of inflammation are rarely increased 
under this treatment even though there was persistence of the inflammatory process. In 
our opinion, the fact that CRP and clinical response were considered together as a 
combined final endpoint may constitute an important limitation of the GiACTA trial 
because it may have overestimated the actual number of remissions due to the favorable 
effect of tocilizumab in decreasing CRP [85**]. 
We feel that a research question that needs to be addressed in daily clinical practice is to 
confirm if biologic agents, in particular tocilizumab, may allow to perform 
glucocorticoid discontinuation in a shorter period of time than conventional 
immunosuppressive agents such as MTX. Also, we feel that although the use of 
tocilizumab appears to decrease the risk of side effects related to glucocorticoid therapy, 
additional studies are required to confirm that early use of this biologic agent may truly 
reduce the risk of severe ischemic complications, such as blindness, in patients with 
GCA.   
Another issue that requires further investigation is to determine if patients with isolated 
PMR undergoing anti-IL-6 receptor tocilizumab therapy, without any vascular 
manifestation, in whom subclinical large vessel involvement is disclosed by imaging 
techniques such as PET/CT scan, are truly protected against the development of sudden 
vascular complications by the use of this biologic agent. On the other hand, we have to 
keep in mind the potential risks, mainly infections, related to the use of biologic 
therapy. Because of that, due to the frequent adverse events of these agents, sometimes 











tocilizumab in particular should only be reserved for some profiles of patients such as 
those with inefficacy to conventional therapy, patients with a history of relapses despite 
a good adherence to treatment, impossibility of tapering off glucocorticoids, patients 
suffering severe adverse effects related to glucocorticoids, in patients with LVV 
refractory to conventional therapy, imminent risk of fatal complications such as stroke 
or at the onset of the treatment in the elderly fragile patients with high burden of 
comorbidities.  
Finally, we think that it is very important to emphasize that the ultimate goal in the 
management of GCA is always to reach sustained remission. This constitutes a 
challenge not yet fully achieved. Because of that, it is possible that new drugs, such as 
the JAK inhibitors that have a broader effect on inflammatory pathways, may be more 
useful for the management of refractory GCA. Nevertheless, further investigation needs 
to be done.  
 
4. Five-year view 
In the near future, it is possible that affordable imaging techniques will allow us to 
make an early diagnosis of the disease. Also, genetic or serological biomarkers will help 
us to identify specific patterns of the disease, in particular to disclose GCA patients at 
risk of severe ischemic complications such as blindness. Although we feel that 
glucocorticoids will still remain as the pivotal therapy for the management of GCA, 
new biologic therapies will be used soon after the diagnosis of the disease in an attempt 
to induce early disease remission and reduce glucocorticoid side effects. In this regard, 
the use of new therapies such as JAK inhibitors or perhaps interferon gamma 












5. Key Issues 
1. GCA is the most common large-vessel vasculitis in individuals older than 50 years 
from Western countries. 
2. Proinflammatory cytokines, such as IL-6, play a key role in the pathogenesis of GCA  
3. In at least 20% of the patients, GCA features are preceded by PMR symptoms. 
4. The main complication of GCA is the development of anterior ischemic optic 
neuropathy that can lead to blindness if early diagnosis and treatment are not performed. 
5. Imaging techniques constitute a major breakthrough in the diagnosis of the disease, 
especially for the assessment of extracranial LVV involvement. 
6. Glucocorticoids are the cornerstone of the therapy in GCA.  
7. In elderly patients, with high burden of comorbidity, conventional 
immunosuppressive agents, such as methotrexate, should be considered in an attempt to 
reduce the cumulative dose of glucocorticoids. 
8. In patients who are refractory to both glucocorticoids and conventional 
immunosuppressive drugs, biologic agents, in particular tocilizumab, must be 
considered for the management of the disease. 
9. Tocilizumab is the only biologic agent approved for the management of GCA. 
10. Adverse effects, especially infections, are not uncommon in patients with GCA 
undergoing biologic therapy. 
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Abbreviations: GCA: Giant Cell Arteritis; IL-6R: interleukin 6 (receptor);  
iv: intravenous; JAK/STAT: Janus kinase/Signal Transducer and Activator of 
Transcription signaling pathway; OP: osteoporosis; TCZ: tocilizumab. 
 
Table 1. Main clinical and laboratory features of patients with biopsy-proven GCA who 
had the typical pattern of cranial GCA in decreasing order of frequency*. Adapted from 
[26]. 
*Frequencies were recalculated using data from studies on the epidemiology of biopsy-proven 
GCA in Lugo (NW Spain).  
 











Table 1. Main clinical and laboratory features of patients with biopsy-proven GCA who 





Headache        85% 
 
Abnormal temporal artery on physical examination   73% 
 
Asthenia, anorexia and weight loss     60% 
 
Jaw claudication on chewing      41% 
 
Polymyalgia rheumatica      40% 
 
Scalp tenderness       33% 
 
Fever (temperature ≥ 38ºC)      10% 
 
Visual ischemic manifestations     23% 
 
Permanent visual loss       13% 
 
Dysphagia        5% 
 
Cerebrovascular accidents      3% 
 




Erythrocyte sedimentation rate > 40 mm/1st hour   99%    
  
 Anemia (hemoglobin < 12 g/dl)     55% 
  
 Thrombocytosis (platelet count > 400.000/mm3)   50% 
 
 Elevation of alkaline phosphatase      25% 
 _____________________________________________________________________ 
GCA: Giant cell arteritis. 
*Frequencies were recalculated using data from studies on the epidemiology of biopsy-












Table 2. Main therapies used in patients with giant cell arteritis. Adapted from [26]. 
_____________________________________________________________________ 
• Classic treatment:  Corticosteroids       
 Prednisone: Initial dose 40-60 mg/day 
Methylprednisolone IV pulse therapy: 1g daily for 3 consecutive days in patients with 
visual ischemic manifestations or other severe ischemic complications 
• Alternative-corticosteroid sparing therapies:  
1) Conventional immunosuppressive drugs: 
Methotrexate (first choice) 
Others such as azathioprine or leflunomide (not commonly used) 
2) Biologic Agents 
a. Anti-IL-6- tocilizumab (useful in GCA refractory to conventional therapy. 
Also, as glucocorticoid-aspiring agent (approved for GCA) 
b. TNF-alpha blockers such as the anti-TNF-alpha monoclonal antibody- 
infliximab (poor results). Not considered for the management of GCA 
c. Others: Abatacept, Ustekinumab, JAnus Kinases inhibitors (insufficient 
information. Further studies are needed) 
• Therapies to aimed to decrease the risk of ischemic complications in patients with 
GCA: Antiagregation therapy (low-dose aspirin: 80-100 mg/day) 
• Drugs for prevention and treatment of glucocorticoid-induced osteoporosis: 
  Calcium and vitamin D along with a potent oral bisphosphonate 
 Denosumab or teriparatide (PTH[1-34]) in selected cases 
___________________________________________________________________ 
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